Company Description
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States.
Its lead products candidate includes avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism.
The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases.
Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2014 |
| IPO Date | Jan 7, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 123 |
| CEO | Joshua B. Cohen |
Contact Details
Address: 43 Thorndike Street Cambridge, Massachusetts 02141 United States | |
| Phone | 617 682 0917 |
| Website | amylyx.com |
Stock Details
| Ticker Symbol | AMLX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001658551 |
| CUSIP Number | 03237H101 |
| ISIN Number | US03237H1014 |
| Employer ID | 46-4600503 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Justin B. Klee | Co-Founder, Co-Chief Executive Officer and Director |
| Joshua B. Cohen | Co-Founder, Co-Chief Executive Officer and Director |
| James M. Frates M.B.A. | Chief Financial Officer |
| Gina M. Mazzariello J.D. | Chief Legal Officer and General Counsel |
| Dr. Camille L. Bedrosian M.D. | Chief Medical Officer |
| Tom Holmes | Chief Technical Operations Officer |
| Lindsey Allen | Head of Investor Relations and Communications |
| Linda A. Arsenault | Chief Human Resources Officer |
| Tammy Sarnelli | Global Head of Regulatory Affairs |
| Dr. Machelle Manuel Ph.D. | Vice President and Head of Global Medical Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 24, 2025 | ARS | Filing |
| Apr 24, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 24, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 26, 2025 | EFFECT | Notice of Effectiveness |
| Mar 5, 2025 | UPLOAD | Filing |
| Mar 4, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 4, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 4, 2025 | 10-K | Annual Report |
| Mar 4, 2025 | POSASR | Filing |
| Mar 4, 2025 | 8-K | Current Report |